In summary, although further studies are required to confirm the safety of PPARβ/δ ligands, these drugs have demonstrated that modulation of PPARβ/δ activity shows efficacy in preclinical studies and in a few clinical trials in the treatment of dyslipidaemia, type 2 diabetes mellitus and NAFLD. This evidence concerns the gene PPARD and metabolic dysfunction-associated steatotic liver disease.